Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Memory Flexibility Training, Psychoeducation · 1 trial · 1 indication
Self report measure of depression symptoms
| Arm | Type | Description |
|---|---|---|
| Memory Flexibility Training | EXPERIMENTAL | The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress. |
| Psychoeducation | PLACEBO_COMPARATOR | The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists. |
| Name | Type | Description |
|---|---|---|
| Memory Flexibility Training | BEHAVIORAL | As in experimental arm description. |
| Psychoeducation | BEHAVIORAL | As in experimental arm description. |
Inclusion Criteria: * Currently experiencing Major Depressive Episode, indexed on the Structured Clinical Interview for the DSM-IV (SCID; First et al., 1996). * Score of 13 or above on the Beck Depression Inventory (Beck et al., 1996) Exclusion Criteria: * SCID assessment indicates they are exper...
Top 20 of 29 competitors
Memory Flexibility Training, Psychoeducation is an investigational intervention being studied for the treatment of Major Depressive Disorder. It is a non-pharmacologic approach that was evaluated in a completed Phase 1 clinical trial in the United Kingdom. The intervention is being developed by Cognition Therapeutics, Inc. (CGTX).
Memory Flexibility Training, Psychoeducation is being developed by Cognition Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker CGTX. The company conducted a Phase 1 clinical trial of this intervention for Major Depressive Disorder, which has been completed.
Memory Flexibility Training, Psychoeducation is in Phase 1 of clinical development. The Phase 1 trial, which has been completed, enrolled 60 participants with Major Depressive Disorder. The intervention is investigational and has not been approved by regulatory authorities.
Memory Flexibility Training, Psychoeducation has one completed clinical trial registered as NCT02371291, titled 'Memory Flexibility Training for Depression.' This Phase 1 study enrolled 60 participants with Major Depressive Disorder in the United Kingdom. The trial was placebo-controlled and randomized, though it was not double-blinded.
Memory Flexibility Training, Psychoeducation is not FDA approved. It is an investigational intervention that has completed a Phase 1 clinical trial for Major Depressive Disorder. The trial, NCT02371291, was conducted in the United Kingdom and enrolled 60 participants. Further clinical development would be required before any regulatory approval could be considered.